Gamida Cell Ltd.

203 articles about Gamida Cell Ltd.

• Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update

  11/15/2021

  Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update

• Gamida Cell Provides Update on Pre-BLA Meeting With FDA for Omidubicel

  11/11/2021

  Gamida Cell Ltd. completed a Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) for omidubice

• Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

  11/9/2021

  Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

• Gamida Cell Announces the Date of Its Third Quarter 2021 Financial Results and Webcast

  11/8/2021

  Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Monday, November 15, 2021, at 8:00 a.m. ET to review its third quarter 2021 financial results and provide an update on the company.

• Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe

  11/4/2021

  Gamida Cell Ltd. today announced that Aviad Pato, Ph.D., Head of Immunology Research, presented data on two nicotinamide (NAM)-enabled NK cell therapies, GDA-501 and GDA-301, at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Barcelona, Spain, and virtually November 2-4, 2021.

• Gamida Cell Announces Data to Be Presented at 63rd ASH Annual Meeting

  11/4/2021

  Gamida Cell Ltd., an advanced cell therapy company committed to cures for cancer and other serious diseases, announced four presentations at the 63rd American Society of Hematology Annual Meeting, which is being held in Atlanta, Georgia or virtually from December 11-14, 2021.

• Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day

  10/26/2021

  Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day

• Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

  10/19/2021

  Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36 th  Annual Meeting

• Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline

  9/28/2021

  Gamida Cell Ltd. today announced that it will host a virtual event detailing the company’s proprietary NAM-enabled natural killer (NK) cell therapy pipeline on Tuesday, October 26, 2021 at 8:00 a.m. ET.

• Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September 2021

  9/2/2021

  Gamida Cell Ltd., an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced that company management will present its corporate highlights at the following virtual investor conferences in September.

• Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update

  8/11/2021

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today reported financial results for the quarter ended June 30, 2021.

• Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast

  8/4/2021

  Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Wednesday, August 11, 2021, at 8:00 a.m. ET to review its second quarter 2021 financial results and provide an update on the company.

• Gamida Cell to Present at the BTIG Virtual Biotechnology Conference

  8/3/2021

  Gamida Cell Ltd. today announced that the company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m. ET.

• Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel)

  6/23/2021

  Gamida Cell Announces Publication in Blood , the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant

• Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June

  6/9/2021

  Gamida Cell Ltd. today announced that company management will present its corporate highlights at the following investor conferences in June.

• Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update

  6/7/2021

  Gamida Cell Ltd., an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced the appointment of Vladimir Melnikov as senior vice president, global operations and manufacturing.

• Gamida Cell to Present at the RBC Capital Markets Global Healthcare Conference

  5/12/2021

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chief executive officer of Gamida Cell, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 3:40 p.m. ET.

• Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update

  5/11/2021

  BLA submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant, expected in fourth quarter of 2021 Pre-commercial and manufacturing activities underway to support potential launch of omidubicel in 2022 Phase 1/2 clinical trial of allogeneic, off-the-shelf GDA-201 in NHL planned with IND submission anticipated in the second half of 2021

• Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and Webcast

  5/4/2021

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, May 11, 2021, at 8:00 a.m. ET to review its first quarter 2021 financial results and provide an update on the company.

• Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

  3/15/2021

  Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) -Abstract will be shared at Presidential Symposium and featured in this year’s “Live with Best Abstracts” session-